Paracrine Factors of Human Fetal MSCs Inhibit Liver Cancer Growth Through Reduced Activation of IGF-1R/PI3K/Akt Signaling
Niacinamide
0301 basic medicine
Biomedical and clinical sciences
Carcinoma, Hepatocellular
Indoles
610
Receptor, IGF Type 1
Phosphatidylinositol 3-Kinases
03 medical and health sciences
Fetus
Genetic
Drug Discovery
Genetics
Sunitinib
Humans
Pyrroles
Molecular Biology
Cell Proliferation
Pharmacology
Drug Discovery3003 Pharmaceutical Science
Phenylurea Compounds
Liver Neoplasms
Mesenchymal Stem Cells
Sorafenib
3. Good health
Biological sciences
Culture Media, Conditioned
Gene Knockdown Techniques
Molecular Medicine
Proto-Oncogene Proteins c-akt
Signal Transduction
DOI:
10.1038/mt.2015.13
Publication Date:
2015-01-26T12:14:42Z
AUTHORS (15)
ABSTRACT
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in world. The multikinase inhibitor sorafenib only demonstrated marginal improvement overall survival for advanced disease prompted search alternative treatment options. Human mesenchymal stem cells (MSCs) have ability to home tumor cells. However, its functional roles on microenvironment remain controversial. Herein, we showed that conditioned media derived from human fetal MSC (CM-hfMSCs) expressed high level insulin growth factor binding proteins IGFBPs and can sequester free insulin-like factors (IGFs) inhibit HCC cell proliferation. inhibitory effect IGF signaling was further evident reduction activated IGF-1R PI3K/Akt, eventually induction cycle arrest. We also CM-hfMSCs could enhance therapeutic efficacy sunitinib. To best our knowledge, this first report show has a tumor-specific, antiproliferative not observed with normal hepatocyte patient-derived matched tissues. Our results thus suggest provide useful tool design alternative/adjuvant strategies HCC, especially related function potentiate effects chemotherapeutic drugs.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (50)
CITATIONS (68)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....